This review highlights the role of 5-HIAA as a biomarker in carcinoid tumours, indicating critical diagnostic applications and therapeutic implications.
5-Hydroxyindoleacetic acid (5-HIAA), the main urinary metabolite of serotonin, is a key biomarker in diagnosing and managing carcinoid tumours. These neuroendocrine tumours, often originating from enterochromaffin cells in the gastrointestinal tract, frequently secrete excess serotonin. After hepatic metabolism, serotonin converts to 5-HIAA, which is excreted in urine. Measuring urinary 5-HIAA provides a non-invasive, cost-effective, and reliable method for detecting functional carcinoid tumours and monitoring disease progression or response to therapy. This review discusses the clinical significance of 5-HIAA, its application in routine monitoring, and factors affecting test accuracy, including diet, medications, renal function, and tumour burden. It also highlights improved detection techniques like high-performance liquid chromatography and LC-MS. Case studies illustrate 5-HIAA’s practical clinical value, while alternative biomarkers such as chromogranin A and pancreatic polypeptide are explored. The article concludes by addressing diagnostic challenges and future directions in neuroendocrine tumour biomarker research and clinical practice.
No takes yet. Share an insight, caveat, or question.
Shrivastav et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: